In Iceland, a study of all children born over an 11-year period, before and after the introduction of pneumococcal conjugate vaccine (PCV) into the national immunization program, found a 6% decrease in all antibiotic prescriptions for children during their first four years of life and a 22% reduction in prescriptions for otitis media after the vaccine was introduced. Thus, in addition to reducing the burden of pneumococcal disease, PCV may also slow the spread of antibiotic resistance.
Full Citation:
Eythorsson E, Sigurdsson S, Hrafnkelsson B. 2018. Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study. BMC Infectious Disease. 18(505).
Title of Article: Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study
Author(s): Eythorsson E, Sigurdsson S, Hrafnkelsson B
Publication Year: 2018
Publication Name: BMC Infectious Disease
Publication Volume: 18(505)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/30286726/
DOI (Digital Object Identifier): 10.1186/s12879-018-3416-y
Topics: Antibiotic Resistance | Global Issues
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: Iceland
WHO Regions: Europe